Corline Biomedical AB

Stockholm Stock Exchange CLBIO.ST

Corline Biomedical AB Shares (Diluted, Weighted) for the year ending December 31, 2023: 21,677,301

Corline Biomedical AB Shares (Diluted, Weighted) is 21,677,301 for the year ending December 31, 2023, a 0.87% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Corline Biomedical AB Shares (Diluted, Weighted) for the year ending December 31, 2022 was 21,490,819, a 5.14% change year over year.
Corline Biomedical AB Shares (Diluted, Weighted) for the year ending December 31, 2021 was 20,439,879, a 19.20% change year over year.
Corline Biomedical AB Shares (Diluted, Weighted) for the year ending December 31, 2020 was 17,148,065, a 2.46% change year over year.
Corline Biomedical AB Shares (Diluted, Weighted) for the year ending December 31, 2019 was 16,736,715, a 7.39% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Stockholm Stock Exchange: CLBIO.ST

Corline Biomedical AB

CEO	Dr. Henrik Nittmar Ph.D.
IPO Date	June 3, 2015
Location	Sweden
Headquarters	Lefflersgatan 5
Employees	13
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Composite Materials Medical Instruments Pharmaceuticals Plastics

Description

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.

Key trends

Past 5 years